Impax Laboratories Inc. Message Board
-
IPXL - Long Term Prospects
You need to give the company a little time. There is a lot on the horizon, and the Company has demonstrated competency.
1. Considerable cash balance.
2. W/o Cash, trades at 8X earnings
3. Management looking at an accretive acquisition. I'd expect $100M to $150M of EBITDA.
4. Expect Adderall XR Sales increases
5. Company is the first to file on Concerta. JNJ's patent was invalidated.
6. Detrol LA - settlement is likely.
7. IPX066 - considerable earnings potential down the road.
8. Manufacturing in Taiwan - costs driven down/tax savings.
8. Pipeline - Doryx 150 mg, Renvela, Effexor XR, Solodyn, Renagel, Amrix, Trilipix, Welchol, Fenoglide, Oracea, Tricor, Cymbalta
Stayed tuned throughout 2011. A LOT on the Horizon.-
Good post, great information for everybody!
it seems as there is lot manipulation on this stock - somebody is trying to steal! This is easy $21 - $26 stock! -
I'm looking forward to seeing IPXL spend some of their cash hoard. They must earn next to nothing on this huge cash balance.
-
IPX066 - is an extended release Carbidopa-Levodopa product for the treatment of late stage Parkinson’s Disease. Approximately 1MM people suffer from Parkinson’s Disease in US. IPXL estimates the prescription market for Parkinson’s Disease is $1.4B. Phase3 data is expected in early 2011.
Hold on folks!- 1 Reply to secrtztn
-
Nice post. thank you.
-